Angiopoietin-2 specific binding agents

Abstract

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

1 . An isolated antibody comprising a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 11 having no more than one amino acid substitution, and said light chain variable region comprising an amino sequence of SEQ ID NO: 12 having no more than one amino acid substitution, and wherein said antibody specifically binds angiopoietin-2 (Ang-2). 
     
     
         2 . The isolated antibody of  claim 1 , wherein said substitution in SEQ ID NO: 11 is in any one of CDR1, CDR2, and CDR3, and wherein said substitution in SEQ ID NO: 12 is in any one of CDR1, CDR2, and CDR3. 
     
     
         3 . The isolated antibody of  claim 1  or  2 , wherein said antibody is a polyclonal, monoclonal, chimeric, humanized, or a fully human antibody. 
     
     
         4 . The isolated antibody of  claim 3 , wherein said antibody is a monoclonal antibody. 
     
     
         5 . The isolated antibody of  claim 4 , wherein said antibody is fully human. 
     
     
         6 . A pharmaceutical composition comprising the isolated antibody of  claim 5  and a pharmaceutically acceptable formulation agent. 
     
     
         7 . An isolated antibody comprising a heavy chain variable region and a light chain variable region, said antibody made by the process of substituting no more than one amino acid in said heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 11, and substituting no more than one amino acid in said light chain variable region comprising an amino acid sequence of SEQ ID NO: 12, and wherein said antibody specifically binds angiopoietin-2 (Ang-2). 
     
     
         8 . The isolated antibody of  claim 7 , wherein said substitution in SEQ ID NO: 11 is in any one of CDR1, CDR2, and CDR3, and wherein said substitution in SEQ ID NO: 12 is in any one of CDR1, CDR2, and CDR3. 
     
     
         9 . The isolated antibody of  claim 7  or  8 , wherein said antibody is a polyclonal, monoclonal, chimeric, humanized, or a fully human antibody. 
     
     
         10 . The isolated antibody of  claim 9 , wherein said antibody is a monoclonal antibody. 
     
     
         11 . The isolated antibody of  claim 10 , wherein said antibody is fully human. 
     
     
         12 . A pharmaceutical composition comprising the isolated antibody of  claim 11  and a pharmaceutically acceptable formulation agent.